One To Watch

MoonLake Immunotherapeutics

A clinical-stage biotechnology company developing sonelokimab, a tri-specific Nanobody targeting IL-17A and IL-17F for inflammatory skin and joint diseases.

Company Overview

MoonLake Immunotherapeutics (NASDAQ: MLTX) is a clinical-stage biopharmaceutical company focused on developing sonelokimab, a tri-specific Nanobody that inhibits IL-17A and IL-17F for the treatment of inflammatory diseases. The company is advancing sonelokimab through multiple late-stage clinical programs in hidradenitis suppurativa (HS), psoriatic arthritis (PsA), axial spondyloarthritis (axSpA), and palmoplantar pustulosis (PPP). MoonLake plans to submit a Biologics License Application for sonelokimab in adult and adolescent HS in the second half of 2026, with a potential first U.S. launch in the second half of 2027.

Headquarters and Global Presence

MoonLake Immunotherapeutics is headquartered in Zug, Switzerland. The company is listed on NASDAQ and conducts global clinical trials across multiple regions. MoonLake has established a $500 million non-dilutive financing agreement with Hercules Capital to support its commercial preparations and pipeline advancement.

Founding and History

MoonLake Immunotherapeutics was founded in 2021, backed by a Series A financing led by BVF Partners LP. The company was established to develop sonelokimab, originally developed as a Nanobody platform asset. MoonLake subsequently listed on NASDAQ under the ticker MLTX and has advanced sonelokimab into Phase III clinical trials across multiple inflammatory indications within five years of founding.

Therapy Areas and Focus

MoonLake focuses on IL-17-driven inflammatory diseases. The company's primary indications include hidradenitis suppurativa, a chronic inflammatory skin condition affecting approximately 1% of the population; psoriatic arthritis, a form of inflammatory arthritis associated with psoriasis; axial spondyloarthritis, an inflammatory disease affecting the spine and sacroiliac joints; and palmoplantar pustulosis, a chronic inflammatory condition of the palms and soles. All target indications share IL-17A and IL-17F as key disease-driving cytokines.

Technology Platforms and Modalities

Sonelokimab is a tri-specific Nanobody, a class of small antibody-derived therapeutics based on single-domain antibody fragments. It simultaneously inhibits IL-17A/A, IL-17A/F, and IL-17F/F homodimers and heterodimers. The Nanobody format offers potential advantages over conventional monoclonal antibodies, including a smaller molecular size that may enhance tissue penetration. Sonelokimab also incorporates an albumin-binding domain to extend its half-life, enabling subcutaneous dosing at intervals convenient for patients.

Key Pipeline and Programs

In hidradenitis suppurativa, Phase III VELA-1 and VELA-2 trials reported Week 40 results in March 2026 at the AAD Annual Meeting, showing 62% HiSCR75 response rates and up to 32% HiSCR100, with up to 77% of patients reaching IHS4-55 and up to 25% meeting an inflammatory remission composite. A BLA submission is planned for the second half of 2026. In psoriatic arthritis, the Phase IIb ARGO trial demonstrated high ACR and PASI response rates versus placebo and an adalimumab reference arm, and two Phase III trials (IZAR-1 and IZAR-2) are underway with key readouts expected in 2026. The Phase II S-OLARIS trial in axial spondyloarthritis is also progressing.

Key Personnel

Jorge Santos da Silva is Co-Founder and Chief Executive Officer. Prior to MoonLake, he spent 14 years at McKinsey & Company, where he was Senior Partner leading the Pharmaceutical & Medical Products Practice, the Biotech group, and the Biosimilars group. Arnout Ploos van Amstel serves as Co-Founder and Chief Operating Officer. Prof. Kristian Reich serves as Co-Founder and Chief Scientific Officer. Matthias Bodenstedt serves as Chief Financial Officer.

Strategic Partnerships

MoonLake entered a $500 million non-dilutive financing agreement with Hercules Capital to support its pipeline development and commercial preparations. The company is building internal commercial capabilities for the anticipated U.S. launch of sonelokimab in hidradenitis suppurativa in the second half of 2027. MoonLake has received a positive outcome from a Type B meeting with the U.S. FDA in January 2026, supporting its BLA submission plans. The company operates as a single-asset company focused on maximizing the commercial potential of sonelokimab across multiple indications.

FAQ Section

MoonLake's central challenge is executing a successful BLA submission for sonelokimab in HS in the second half of 2026 while simultaneously building commercial infrastructure for a potential 2027 U.S. launch and advancing Phase III trials in psoriatic arthritis.

Both IL-17A and IL-17F drive inflammation in conditions like HS and PsA, but most existing therapies only target IL-17A. Simultaneously blocking all three IL-17 dimer forms (A/A, A/F, F/F) may provide deeper and more durable anti-inflammatory responses than selective IL-17A inhibition alone.

Sonelokimab's tri-specific Nanobody format provides broader IL-17 pathway coverage than conventional anti-IL-17A antibodies, combined with a smaller molecular size that may enhance tissue penetration. The Week 40 Phase III data showing 62% HiSCR75 and 32% HiSCR100 in HS represents a high bar for the class.

Sonelokimab is a potential first-in-class tri-specific IL-17 inhibitor with strong Phase III efficacy data in HS and Phase IIb data in PsA. If approved, it would be among the first targeted biologics specifically developed for HS, a disease with limited approved treatment options.

The pipeline spans inflammatory dermatology (HS, PPP), rheumatology (PsA, axSpA), and potentially additional IL-17-driven conditions. All programs use the same molecule, sonelokimab, applied across different indications sharing IL-17 as a key disease driver.

MoonLake is in late clinical development with a near-term regulatory filing. Phase III HS trials have reported positive Week 40 data, and a BLA submission is planned for the second half of 2026. Phase III PsA trials are underway with readouts expected in 2026.

Key watchpoints include the BLA submission timing and FDA acceptance for sonelokimab in HS, Phase III readouts from IZAR-1 and IZAR-2 in psoriatic arthritis, the company's ability to build commercial infrastructure ahead of a potential 2027 launch, and competitive dynamics with other HS and IL-17 therapies.

Want to Update your Company's Profile?